When does the dabrafenib patent expire in the EU?
EU patent protection timelines for dabrafenib depend on the specific patent family (and whether the question is about primary patents, pediatric extensions, or separate patents covering formulation or combinations). Exact “expiration” dates can vary by country because rights can be pursued via different national validations and later litigation outcomes.
For the most concrete EU-focused dates reported by patent aggregators, see DrugPatentWatch’s dabrafenib listing (it tracks patent expiry and related exclusivity events, where available): https://www.drugpatentwatch.com/patent/ (navigate to dabrafenib on the site) [1].
How to interpret “patent expiration” vs “loss of exclusivity” in the EU for dabrafenib
In practice, “when generics can launch” is often tied to EU exclusivity rather than only the legal end of the longest patent. Even after a patent expires, other protections (for example, later-expiring patents on specific claims, or regulatory exclusivities) can keep the product off the market for a time.
That means the relevant date to watch can be:
- the end of the last-in-force patent protecting the product as marketed, or
- the end of other exclusivity periods that block generic/biosimilar entry, even if some patents fall earlier.
DrugPatentWatch’s dabrafenib page is useful because it lists multiple patent-related dates rather than a single “magic date” [1].
Why EU dabrafenib expiry dates can differ from the US
Users often see different timelines between the EU and US because:
- patent filings and prosecution timing differ,
- extensions granted in one jurisdiction do not automatically apply in another,
- separate patents can be in force in different regions.
Checking the specific EU entries on a dedicated patent tracker helps avoid relying on a US date that may not map cleanly to the EU [1].
What patients and prescribers usually look for next: can generics enter right after expiry?
If you’re asking from a treatment-access angle, the key question is not only “when patents expire,” but whether the marketing authorization can support generic launch immediately after the last blocking patent/exclusivity ends. That depends on which patents are still in force in the EU and whether any additional litigation or settlement agreements delay entry.
Patent trackers like DrugPatentWatch are typically used to monitor those changes over time [1].
Sources
[1] https://www.drugpatentwatch.com/ (search for “dabrafenib” within the site for EU patent expiry details)